Cyxone
Life-changing treatments for disorders of the immune system
Life-changing treatments for disorders of the immune system
Cyxone is a Swedish clinical biotech company that focuses on developing immunomodulating drugs for treating autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company's portfolio includes rabeximod, currently in a clinical phase II program for RA, and T20K, which has completed a phase I infusion study for MS. Cyxone aims to address the unmet need for new, effective, and safe medicines to enhance the quality of life for patients with autoimmune diseases. Founded in 2015, the company operates in the biotechnology and health care industries, with its headquarters in Sweden. Despite the absence of recent disclosed investments and investors, Cyxone's focus on addressing autoimmune diseases through innovative drugs positions it as a potential opportunity for venture capital looking to invest in the biotech sector.
There is no investment information
No recent news or press coverage available for Cyxone.
We care about your data, and we'd love to use cookies make your experience better.